As a purpose-fueled, people-centric drug delivery CDMO, we are dedicated to advancing programs that help fast-track healthier tomorrows. Our US facilities play a vital role in delivering this commitment, providing specialized environments, technical depth and operational excellence that extend beyond manufacturing.
Our US sites are strategically located and designed to support complex drug delivery programs from development through to commercial manufacturing. These sites reflect our focus on quality, scalability and long-term partnerships across injectable and nasal treatments.
In this video, we explore severalKindeva facilities across the US, highlighting how our capabilities and infrastructure are designed to help support you at critical stages of your product’s lifecycle.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
Explore our world-class sterile injectable facility in Bridgeton, Missouri | Video tour
Spanning over 155,000 sq. ft. of dedicated aseptic operations space, our Bridgeton, MO facility brings together leading expertise, advanced automation and Annex 1-compliant isolator technology to help support growing global demand for sterile injectables. Designed to deliver excellence from floor to ceiling, Bridgeton seamlessly connects development and delivery through flexible fill finish infrastructure that helps […]
Learn MorePharmaSource podcast with Tommy Schornak
Today’s pharmaceutical companies must manage tight timelines and high demand for products, as well as shifting regulatory requirements and an increasingly complex global supply chain. How can contract development and manufacturing organizations (CDMOs) rise to this challenge and provide the support they need? In this podcast with PharmaSource, Tommy Shornak, Senior Vice President, Sterile Injectables, […]
Learn MoreThe bridge to uncompromising fill finish precision
Sterile fill finish is a sequence of tightly connected control points, where performance at each stage directly influences quality, timelines and patient safety. Bridgeton is designed to deliver control at every step of the fill finish journey. Our 155,000 sq. ft. aseptic facility combines advanced automation, gloveless isolator technology and structured process design to reduce […]
Learn MoreThe bridge to the future of sterile injectables
Access a sterile fill finish solution designed to help your product progress from formulation through commercial scale with greater confidence and control. Having invested over $200M in our purpose-built, Annex 1-aligned facility in Bridgeton, MO, we bring together the infrastructure, expertise and control needed to accelerate your path to market. From early development through to […]
Learn MoreYour bridge to commercial sterile manufacturing
Sterile fill finish has changed. Annex 1 compliance and data transparency are no longer future considerations; they are the baseline. At the same time, programs are expected to move faster, scale seamlessly and maintain absolute control from the first clinical batch through commercial supply. Siloed models cannot keep up with the pace and control required […]
Learn MoreManufacturing more sustainable tomorrows for pulmonary care
The shift to more sustainable inhalers is gaining pace. As pressure grows to reduce their environmental impact, low-Global Warming Potential (GWP) propellants are becoming an important part of the future of metered dose inhaler (MDI) development. In this infographic, we explore the trends shaping that transition, and share how Kindeva is helping partners prepare for […]
Learn MoreParenteral precision: Annex 1-ready sterile fill finish by design
Parenteral precision is a blog series exploring the controls, technologies and design decisions that shape modern parenteral manufacturing. Each article looks at one capability through a practical lens: what it is, how it works, who it supports and why it matters. This first blog focuses on Annex 1-ready sterile fill finish. As the European Union […]
Learn MoreBeyond the bench: Aerosol analysis and the physics of MDI performance
Modern drug delivery is built on an architecture of precision and predictability to ensure patient safety. Behind every successful inhalation therapy lies a methodical application of analytical science that characterizes the behavior of complex aerosol systems. In this Beyond the bench blog, we examine how this analytical backbone supports the development of pressurized metered-dose inhalers […]
Learn MorePowering every breath you give: Our world-class Loughborough site
Pulmonary drug delivery is undergoing a period of rapid change. Developers must bring increasingly complex therapies to market while preparing inhalers for the transition to low-Global Warming Potential (GWP) propellant technologies. Success depends on having expertise across formulation, device integration and scalable manufacturing capabilities. Kindeva’s Loughborough, UK facility stands ready for this evolution. Our global […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.